Cargando…
GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies
After the first case of Coronavirus disease 2019 (COVID-19) was reported in Wuhan, COVID-19 has rapidly spread to almost all parts of world. Angiotensin converting enzyme 2 (ACE2) receptor can bind to spike protein of SARS-CoV-2. Then, the spike protein of SARS-CoV-2 can be cleaved and activated by...
Autores principales: | Wu, Ching-Yuan, Lin, Yu-Shih, Yang, Yao-Hsu, Shu, Li-Hsin, Cheng, Yu-Ching, Liu, Hung Te |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547400/ https://www.ncbi.nlm.nih.gov/pubmed/33049583 http://dx.doi.org/10.1016/j.biopha.2020.110816 |
Ejemplares similares
-
GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2
por: Tsai, Ming-Shao, et al.
Publicado: (2021) -
Anisomeles indica Extracts and Their Constituents Suppress the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro
por: Chen, Yu-Ru, et al.
Publicado: (2023) -
Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations
por: Tsai, Ming-Shao, et al.
Publicado: (2022) -
Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
por: Wu, Ching-Yuan, et al.
Publicado: (2020) -
Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19
por: Li, Hsin-Hsien, et al.
Publicado: (2021)